Issue 12, 2013

Dual mode of action of phenyl-pyrazole-phenyl (6-5-6 system)-based PPI inhibitors: alpha-helix backbone versus alpha-helix binding epitope

Abstract

A new class of alpha-helix mimetics, based on the phenyl-pyrazole-phenyl (6-5-6) system, has been designed and synthesized. The ability of the new compounds to inhibit PPIs was confirmed using an MDM2-p53 binding assay. The library, containing completely new compounds, revealed an excellent hit rate of 15%, had satisfactory physicochemical properties (~38% soluble compounds), and the ligand efficiency of the best compound was 0.21 (0.22 for nutlin-3 in the same assay). Dual mode of action of these inhibitors was suggested based on computer modeling: depending on the nature of their substituents they could act as either an alpha-helix backbone mimetic or an alpha-helix binding epitope mimetic.

Graphical abstract: Dual mode of action of phenyl-pyrazole-phenyl (6-5-6 system)-based PPI inhibitors: alpha-helix backbone versus alpha-helix binding epitope

Supplementary files

Article information

Article type
Concise Article
Submitted
24 Jul 2013
Accepted
20 Sep 2013
First published
20 Sep 2013

Med. Chem. Commun., 2013,4, 1597-1603

Dual mode of action of phenyl-pyrazole-phenyl (6-5-6 system)-based PPI inhibitors: alpha-helix backbone versus alpha-helix binding epitope

N. I. Vasilevich, I. I. Afanasyev, E. A. Rastorguev, D. V. Genis and V. S. Kochubey, Med. Chem. Commun., 2013, 4, 1597 DOI: 10.1039/C3MD00211J

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements